FEASIBILITY OF [64CU]CU-TRASTUZUMAB PET/CT IMAGING IN BREAST CANCER: A SYSTEMATIC REVIEW
Main Article Content
Keywords
[64Cu]Cu-trastuzumab, PET/CT, Breast Cancer, HER2
Abstract
Purpose: [64Cu]Cu-NOTA/DOTA-trastuzumab PET/CT imaging can non-invasively identify human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). In addition to presenting literature-based evidence for dosimetry and pharmacologic safety of [64Cu]Cu- NOTA/DOTA-trastuzumab in patients, this systematic review aims to demonstrate the viability of [64Cu]Cu-trastuzumab PET/CT in identifying and assessing trastuzumab tumor uptake in people with HER2-positive metastatic BC.
Methods: We searched the PubMed, Scopus, and EMBASE databases to find pertinent English-language papers concerning [64Cu]Cu- NOTA/DOTA-trastuzumab PET/CT for BC diagnosis. Other items were also manually searched.
Conclusion: The feasibility of [64Cu]Cu -trastuzumab PET/CT for the identification of HER2-positive lesions was reviewed. [64Cu]Cu-DOTA/NOTA-trastuzumab reveals HER2-positive metastatic BC with high sensitivity and is effective in surveying distributed disease. Moreover, [64Cu] Cu-labeled trastuzumab may possibly be applied to decide on the right patients and right timing for HER2 therapy, to observe the treatment response after HER2-targeted therapy, and not only for the detection of primary HER2-positive BC but also for metastatic HER2-positive lesions. The advancement of [64Cu]Cu-trastuzumab PET/CT for the detection of BC is encouraging. However, more studies are required to determine the usefulness rate of imaging plans for clinical administrations.
References
2. Jiang, H. and H.S. Rugo, Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Therapeutic Advances in Medical Oncology, 2015. 7(6): p. 321-339.
3. Mortimer, J.E., et al., Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer. Journal of Nuclear Medicine, 2018. 59(1): p. 38-43.
4. Woo, S.K., et al., Development of (64)Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. J Nucl Med, 2019. 60(1): p. 26-33.
5. Chmielecki, J., et al., Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. The oncologist, 2015. 20(1): p. 7-12.
6. Singh, J., K. Jhaveri, and F. Esteva, HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. British journal of cancer, 2014. 111(10): p. 1888-1898.
7. De Korte, M., et al., 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. European Journal of Cancer, 2007. 43(14): p. 2046-2051.
8. Perik, P.J., et al., Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol, 2006. 24(15): p. 2276-82.
9. Robinson, M.K., et al., Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Research, 2005. 65(4): p. 1471-1478.
10. Reddy, S., et al., Evaluation of the anti-HER2 C6. 5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clinical Cancer Research, 2011. 17(6): p. 1509-1520.
11. Munnink, T.H.O., et al., 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. European Journal of Cancer, 2010. 46(3): p. 678-684.
12. Dijkers, E., et al., Biodistribution of 89Zr‐trastuzumab and PET imaging of HER2‐positive lesions in patients with metastatic breast cancer. Clinical Pharmacology & Therapeutics, 2010. 87(5): p. 586-592.
13. Tamura, K., et al., 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. Journal of Nuclear Medicine, 2013. 54(11): p. 1869-1875.
14. Li, Z.-B., et al., Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clinical Cancer Research, 2008. 14(15): p. 4758-4766.
15. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine, 2009. 151(4): p. 264-269.
16. Carrasquillo, J.A., et al., Copper-64 trastuzumab PET imaging: a reproducibility study. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of.. 2016. 63(2): p. 191-198.
17. Kurihara, H., et al., 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI research, 2015. 5(1): p. 1-8.
18. Lee, I., et al., A preliminary clinical trial to evaluate 64 Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer. EJNMMI research, 2021. 11(1): p. 1-9.
19. Mortimer, J.E., et al., Functional imaging of human epidermal growth factor receptor 2–positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. Journal of Nuclear Medicine, 2014. 55(1): p. 23-29.
20. Sasada, S., et al., 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Annals of Oncology, 2017. 28(8): p. 2028-2029.
21. Anderson, C.J. and R. Ferdani, Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biotherapy and Radiopharmaceuticals, 2009. 24(4): p. 379-393.
22. Szelecsényi, F., G. Blessing, and S. Qaim, Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: Possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Applied Radiation and Isotopes, 1993. 44(3): p. 575-580.
23. McCarthy, D.W., et al., Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nuclear medicine and biology, 1997. 24(1): p. 35-43.
24. Zweit, J., et al., Excitation functions for deuteron induced reactions in natural nickel: production of no-carrier-added 64Cu from enriched 64Ni targets for positron emission tomography. International journal of radiation applications and instrumentation. Part A. Applied radiation and isotopes, 1991. 42(2): p. 193-197.
25. Obata, A., et al., Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron. Nuclear medicine and biology, 2003. 30(5): p. 535-539.
26. McCarthy, D.W., et al., High purity production and potential applications of copper-60 and copper-61. Nuclear medicine and biology, 1999. 26(4): p. 351-358.
27. Zeisler, S., et al., Production of 64Cu on the Sherbrooke TR-PET cyclotron. Journal of Radioanalytical and Nuclear Chemistry, 2003. 257(1): p. 175-177.
28. Avila-Rodriguez, M.A., J.A. Nye, and R.J. Nickles, Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Applied Radiation and Isotopes, 2007. 65(10): p. 1115-1120.
29. Szajek, L.P., et al., Semi-remote production of [64Cu] CuCl2 and preparation of high specific activity [64Cu] Cu-ATSM for PET studies. Radiochimica Acta, 2005. 93(4): p. 239-244.
30. Lewis, J.S., et al., Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. Journal of Nuclear Medicine, 1999. 40(1): p. 177-183.
31. Ménard, S., et al., HER2 as a prognostic factor in breast cancer. Oncology, 2001. 61(Suppl. 2): p. 67-72.
32. Yan, M., et al., HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer and Metastasis Reviews, 2015. 34: p. 157-164.
33. Yarden, Y., Biology of HER2 and its importance in breast cancer. Oncology, 2001. 61(Suppl. 2): p. 1-13.
34. Graus-Porta, D., et al., ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO journal, 1997. 16(7): p. 1647-1655.
35. van de Vijver, M.J., et al., Neu-protein overexpression in breast cancer. New England Journal of Medicine, 1988. 319(19): p. 1239-1245.
36. Hudis, C.A., Trastuzumab—mechanism of action and use in clinical practice. New England journal of medicine, 2007. 357(1): p. 39-51.
37. Holland, J.P., et al., In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Physics in Medicine & Biology, 2009. 54(7): p. 2103.
38. Obata, A., et al., Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis (N 4-methylthiosemicarbazone)(Cu-ATSM) in tumor cells. Annals of nuclear medicine, 2001. 15(6): p. 499-504.
39. Ren, Q., et al., Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of 64Cu-Trastuzumab. Molecular pharmaceutics, 2019. 16(3): p. 1065-1073.
40. Wong, K., et al., 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a Phase I trial. Pharmaceuticals, 2022. 15(7): p. 772.
41. Li, H., et al., 64Cu-labeled ubiquitin for PET imaging of CXCR4 expression in mouse breast tumor. ACS omega, 2019. 4(7): p. 12432-12437.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Ali Abdulhasan Kadhim
Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran
Peyman Sheikhzadeh
Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran
Mehrshad Abbasi
Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran
Nasim Vahidfar
Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran
Saeed Afshar
Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran
Mohsen Bakhshi Kashi
Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran
Negisa Seyyedi
Nursing and Midwifery Care Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran
Mohammad Reza Ay
Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran